Catch up with what Optometry Times shared this week:

Bausch + Lomb announces Blink NutriTears launch in the US

By Martin David Harp, Associate Editor, Ophthalmology Times

Bausch + Lomb Corporation has announced the official US launch of its Blink NutriTears, a nutritional supplement for the treatment of dry eyes.

According to the company, Blink NutriTears “target the key root causes of dry eyes, promote healthy tear production and provide noticeable relief of dry eye symptoms in as little as 2 to 4 weeks.”

Read here...

Harrow announces data at week 52 from ESSENCE-2 open-label extension study

By David Hutton, Managing Editor, Ophthalmology Times

Harrow announced results from its ESSENCE 2 open-label extension (OLE) clinical study for cyclosporine ophthalmic solution (Vevye) 0.1% to treat the signs and symptoms of dry eye disease (DED).

According to a news release, ESSENCE-2 OLE was a Phase 3, prospective, multicenter, open-label, clinical study with 202 patients, who had previously completed the ESSENCE 2 study, receiving cyclosporine ophthalmic solution in each eye twice a day for 52 weeks.

Read here...

Nordic Pharma announces commercial launch of Lacrifill canalicular gel

By Jordana Joy, Associate Editor

Nordic Group BV’s subsidiary Nordic Pharma announced the commercial launching of its Lacrifill canalicular gel, a novel therapy for dry eye disease (DED) in the US.1 The gel is a cross-linked hyaluronic acid derivative and has been cleared by the FDA to temporarily block tear drainage by the occlusion of the canalicular system, according to a news release.

Read here...

New handheld pachymeter launched by Lumibird division

By Jordana Joy, Associate Editor

Quantel Medical, a division of Lumibird Medical, has announced the launch of its new POCKET III handheld pachymeter. According to a news release, the pachymeter is the lightest handheld product on the market, weighing in at 60 grams.¹

"In addition to the importance of being able to calculate corneal thickness in pre-refractive surgery, pachymetry is essential to calculate and correlate with intraocular pressure. In fact, 80 million* people suffer from glaucoma,” said François Checinski, Ultrasound product manager, in the release.

Read here...

Azura Ophthalmics enrolls first patient in Phase 3 clinical trial for AZR-MD-001 in patients with MGD

By Jordana Joy, Associate Editor

Clinical-stage biopharmaceutical company Azura Ophthalmics announced that the first patient has been enrolled in the company’s Phase 3 clinical trial for its Assessment of Secretions and Treatment for Restoring Ocular Surface Health in Patients with Meibomian Gland Dysfunction (ASTRO) study.¹ The trial is aiming to evaluate the efficacy, safety, and tolerability of sterile ophthalmic ointment (AZR-MD-001) 0.5% compared to vehicle in patients with abnormal meibomian gland function (MGD) and associated symptoms of dry eye disease (DED), according to a news release.

Read here...